Table 2 Drug-pathway association in the DTPN of luminal B subtype
Drug | Pathway | nNE and PCI (vs NE = 0.3272) |
|---|---|---|
Docetaxel | Germ cell-sertoli cell junction signaling (1); epithelial adherens junction signaling (2) | (1) 0.3256 (PCI 0.46%) (2) 0.3196 (PCI 2.30%) (1–2) 0.3180 (PCI 2.80%) |
Fulvestrant | Estrogen-mediated S-phase entry | 0.327093 (PCI 0.03%) |
Raloxifene | Estrogen-mediated S-phase entry | 0.327093 (PCI 0.03%) |
Tamoxifen | Wnt/catenin signaling (1); regulation of the epithelial-mesenchymal transition pathway (2); estrogen-mediated S-phase entry (3) | (1) 0.3254 (PCI 0.53%) (2) 0.3201 (PCI 2.14%) (3) 0.3270 (PCI 0.03%) (1–2) 0.3182 (PCI 2.73%) (1–3) 0.3251 (PCI 0.64%) (3–2) 0.3196 (PCI 2.29%) (1–2–3) 0.3174 (PCI 3.06%) |